Cumberland Pharmaceuticals Inc
NASDAQ:CPIX

  • LAST PRICE
    1.0600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.0600/ 3
  • Ask / Lots
    1.1500/ 1
  • Open / Previous Close
    --- / 1.0600
  • Day Range
    ---
  • 52 Week Range
    1.0400
    2.3587
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:29PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: CPIX
      04:29 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:29PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: CPIX
      04:29 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
      Companies Mentioned: CPIX

      New Real World Study of 150,000 Patients Favors Caldolor over ketorolac -

      DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations -

      Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: CPIX
      credit (29,681,472) (27,051,875) Cash settlement of contingent consideration (1,251,499) (2,108,933) Payments made in connection with repurchase of common shares (480,666) (551,563) ---------------------- ------------------------ Net cash provided by (used in) financing activities 1,575,283 (5,937,371) ---------------------- ------------------------ Net decrease in cash and cash equivalents (856,870) (1,250,005) Cash and cash equivalents at beginning of period $ 18,321,624 $ 19,757,970 ---------------------- ------------------------ Cash and cash equivalents at end of period $ 17,464,754 $ 18,507,965 ====================== ======================== CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share (Unaudited) Three months ended Three months ended September 30, September 30, 2024 2024 2023 2023 ---------------- -------------------- ---------------- -------------------- Earnings Earnings per Earnings Earnings per impact share impact impact share impact Net loss attributable to common shareholders $ (1,544,081) $ (0.11) $ (1,049,298) $ (0.07) Less: Net (income) loss at subsidiary attributable to noncontrolling interests (7,112) -- 13,921 -- ---------------- -------------------- ---------------- -------------------- Net loss (1,536,969) (0.11) (1,063,219) (0.07) Adjustments to net loss Income tax expense 11,442 -- 6,938 -- Depreciation and amortization 1,116,036 0.08 1,221,837 0.08 Share-based compensation (a) 76,371 0.01 83,112 0.01 Interest income (69,190) -- (98,603) (0.01) Interest expense 137,374 0.01 110,081 0.01 ---------------- -------------------- ---------------- -------------------- Adjusted earnings (loss) and adjusted diluted earnings (loss) per share $ (264,936) $ (0.02) $ 260,146 $ 0.02 ================ ==================== ================ ==================== Diluted weighted-average common shares outstanding: 14,052,754 14,422,274 ==================== ==================== Nine months ended Nine months ended September 30, September 30, -------------------------------------- ---------------------------------------- 2024 2024 2023 2023 Earnings Earnings per Earnings Earnings per impact share impact impact share impact Net income (loss) attributable to common shareholders $ (4,575,956) $ (0.32) $ 15,086 $ -- Less: Net (income) loss at subsidiary attributable to noncontrolling interests (33,878) -- 43,865 -- ---------------- -------------------- ----------------- --------------------- Net loss (4,542,078) (0.32) (28,779) -- Adjustments to net loss Income tax expense 34,327 -- 20,813 -- Depreciation and amortization 3,406,166 0.24 3,702,687 0.25 Share-based compensation (a) 227,083 0.02 271,146 0.02 Interest income (227,777) (0.02) (205,854) (0.01) Interest expense 382,247 0.03 489,069 0.03 ---------------- -------------------- ----------------- --------------------- Adjusted earnings (loss) and adjusted diluted earnings (loss) per share $ (720,032) $ (0.05) $ 4,249,082 $ 0.29 ================ ==================== ================= ===================== Diluted weighted-average common shares outstanding: 14,089,496 14,559,687 ==================== =====================

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: CPIX
      credit (29,681,472) (27,051,875) Cash settlement of contingent consideration (1,251,499) (2,108,933) Payments made in connection with repurchase of common shares (480,666) (551,563) ---------------------- ------------------------ Net cash provided by (used in) financing activities 1,575,283 (5,937,371) ---------------------- ------------------------ Net decrease in cash and cash equivalents (856,870) (1,250,005) Cash and cash equivalents at beginning of period $ 18,321,624 $ 19,757,970 ---------------------- ------------------------ Cash and cash equivalents at end of period $ 17,464,754 $ 18,507,965 ====================== ======================== CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share (Unaudited) Three months ended Three months ended September 30, September 30, 2024 2024 2023 2023 ---------------- -------------------- ---------------- -------------------- Earnings Earnings per Earnings Earnings per impact share impact impact share impact Net loss attributable to common shareholders $ (1,544,081) $ (0.11) $ (1,049,298) $ (0.07) Less: Net (income) loss at subsidiary attributable to noncontrolling interests (7,112) -- 13,921 -- ---------------- -------------------- ---------------- -------------------- Net loss (1,536,969) (0.11) (1,063,219) (0.07) Adjustments to net loss Income tax expense 11,442 -- 6,938 -- Depreciation and amortization 1,116,036 0.08 1,221,837 0.08 Share-based compensation (a) 76,371 0.01 83,112 0.01 Interest income (69,190) -- (98,603) (0.01) Interest expense 137,374 0.01 110,081 0.01 ---------------- -------------------- ---------------- -------------------- Adjusted earnings (loss) and adjusted diluted earnings (loss) per share $ (264,936) $ (0.02) $ 260,146 $ 0.02 ================ ==================== ================ ==================== Diluted weighted-average common shares outstanding: 14,052,754 14,422,274 ==================== ==================== Nine months ended Nine months ended September 30, September 30, -------------------------------------- ---------------------------------------- 2024 2024 2023 2023 Earnings Earnings per Earnings Earnings per impact share impact impact share impact Net income (loss) attributable to common shareholders $ (4,575,956) $ (0.32) $ 15,086 $ -- Less: Net (income) loss at subsidiary attributable to noncontrolling interests (33,878) -- 43,865 -- ---------------- -------------------- ----------------- --------------------- Net loss (4,542,078) (0.32) (28,779) -- Adjustments to net loss Income tax expense 34,327 -- 20,813 -- Depreciation and amortization 3,406,166 0.24 3,702,687 0.25 Share-based compensation (a) 227,083 0.02 271,146 0.02 Interest income (227,777) (0.02) (205,854) (0.01) Interest expense 382,247 0.03 489,069 0.03 ---------------- -------------------- ----------------- --------------------- Adjusted earnings (loss) and adjusted diluted earnings (loss) per share $ (720,032) $ (0.05) $ 4,249,082 $ 0.29 ================ ==================== ================= ===================== Diluted weighted-average common shares outstanding: 14,089,496 14,559,687 ==================== =====================

Peers Headlines